Author

Edouard Louis 1

1 University Hospital of Liège

AbbVie - Are we ready to change the course of IBD?

Edouard Louis, Remo Panaccione, Laurent Peyrin-Biroulet, Jean-Frederic Colombel

Biomarkers

Edouard Louis

CHARACTERISTICS OF CHILDREN WITH CROHN?S DISEASE FAILING SUSTAINED REMISSION DESPITE ANTI-TNF EXPOSURE

Lucas Wauters, Françoise Smets, Ilse Hoffman, Elisabeth De Greef, Patrick Bontems, Philippe Alliet, Wim Arts, Bruno Hauser, Stephanie Van Biervliet, Els Van de Vijver, Isabelle Paquot, Harald Peeters, Peter Bossuyt, Jean François Rahier, Tom Moreels, Olivier Dewit, Denis Franchimont, Vinciane Muls, Fernand Fontaine, Edou

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active ulcerative colitis: results from the SERENE-UC induction study

Julian Panés, Jean-Frederic Colombel, Geert R. D'Haens, Stefan Schreiber, Remo Panaccione, Laurent Peyrin-Biroulet, Edward Loftus, Jr, Silvio Danese, Edouard Louis, Alessandro Armuzzi, Marc Ferrante, Harald Vogelsang, Jessica Lefebvre, Thao Doan, Nisha V. Kwatra, Nael M. Mostafa, Wangang Xie, Bidan Huang, Joel Petersson;;

HOSPITALIZATION RATES IN PATIENTS WITH CROHN’S DISEASE AND DEEP REMISSION: DATA FROM THE 56-WEEK CHARM TRIAL

Jean-Frederic Colombel, Remo Panaccione, Edouard Louis, Mei Yang, Martha Skup, Roopal B Thakkar, Parvez Mulani, Jingdong Chao, William Sandborn

Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

Edouard Louis, Peter Bossuyt, Julian Panés, Brian G. Feagan, Jasmina Kalabic, Kori Wallace, Naijun Chen, Wan-Ju Lee, Marc Ferrante

LONG-TERM OUTCOME AFTER INFLIXIMAB WITHDRAWAL FOR SUSTAINED REMISSION IN CROHN’S DISEASE

Catherine Reenaers, Maria Nachury, Yoram Bouhnik, David Laharie, Matthieu Allez, Jean-Louis Dupas, Aurelien Amiot, Guillaume Savoye, Romain Altwegg, Georgia Malamut, Arnaud Bourreille, Bernard Flourie, Philippe Marteau, Lucine Vuitton, Benoit Coffin, Stéphanie Viennot, Jean-Frederic Colombel, Jean Yves Mary, Edouard Louis

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Marc Ferrante, Julian Panés, Filip Baert, Edouard Louis, Arthur Kaser, Dawn Gustafson, David Hall, Wulf O. Böcher, Ivona Herichova, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MADCAM-1 MONOCLONCAL ANTIBODY SHP647 IN CROHN'S DISEASE: THE OPERA II STUDY

Geert R. D'Haens, Walter Reinisch, Scott D. Lee, Dino Tarabar, Edouard Louis, Maria Kłopocka, Jochen G. Klaus, Stefan Schreiber, Dong Il Park, Xavier Hebuterne, Fabio Cataldi, Steven W Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth Gorelick, William Sandborn

LABEL FREE PROTEOMICS IDENTIFIES OLFACTOMEDIN-4 AS A MARKER OF EPITHELIAL TRANSITION OF EARLY CRC STAGES

Florence Quesada-Calvo, Marie-Alice Meuwis, Virginie Bertrand, Rémi Longuespée, Noella Bletard, Joan Somja, Gabriel Mazzucchelli, Nicolas Smargiasso, Dominique Baiwir, Marie-Claire Gillet, Philippe Delvenne, Michel Malaise, Marc Polus, Edwin De Pauw, Edouard Louis

Item 1 - 10 / 50
1
2 3 4 5